Viewing Study NCT01494870



Ignite Creation Date: 2024-05-06 @ 12:07 AM
Last Modification Date: 2024-10-26 @ 10:45 AM
Study NCT ID: NCT01494870
Status: UNKNOWN
Last Update Posted: 2012-01-10
First Post: 2011-12-13

Brief Title: Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block
Sponsor: Samara Regional Cardiology Dispensary
Organization: Samara Regional Cardiology Dispensary

Study Overview

Official Title: None
Status: UNKNOWN
Status Verified Date: 2012-01
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of this study is to propose new treatment algorithm strategy for patients with Acute Coronary Syndrome ACS and left bundle-branch block LBBB
Detailed Description: Current recommendations on the treatment of acute coronary syndrome ACS dictate urgent reperfusion therapy in the case of evolving myocardial infarction with ST-segment elevation STEMI Optimal use of PCI preferably or thrombolysis in this situation requires a rapid and correct diagnosis

According to the ESC2008 and ACCAHA2009 focused update guidelines patients admitted to the hospital within 12 hours after the onset of chest pain with new or presumably new left bundle-branch block LBBB should be treated like patients having STEMI class I level A However it is well-known that in patients with concomitant LBBB the ECG manifestations of acute myocardial injury may be masked

ACS may occur in a patient with true old LBBB when doctor hashas not an ability to compare the new ECG with the previous one or presumably new LBBB

There is a high risk of non receiving appropriate therapy or of receiving inappropriate therapy thrombolysis instead of LMWHUFHfondaparinux

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None